|
|
|
European Biopharmaceutical Review
|
| In the midst of war, these are uncertain times to be going about the daily business of biotech with stock markets initially surging on the news and then reacting unpredictably to specific developments in the conflict. Given the consistently poor market conditions over the last two years, many of the smaller private companies will probably not see much difference in terms of the environment. There is still next to no short-term scope to access funding via the public markets, which continue to exert downward pressure on valuation of private companies, and maintain the high-level scrutiny by venture capital investors in private funding rounds. |
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
Paediatric Clinical Trials
21-22 March 2012, Copthorne Tara Hotel, London, United Kingdom
Designing accurate and safe paediatric formulations is one of the topics being discussed at SMi’s Paediatric Clinical Trials held on 21st & 22nd March 2012
More info >> |
|
 |
News and Press Releases |
 |
Kallik’s new approach to asset management delivers long term artwork automisation
Marketing and compliance departments can now have greater control over their assets –from logos and images to labelling copy – and a roadmap to automated artwork generation, thanks to Kallik’s online Asset Repository. It is the most cost-effective way to lay the foundation for future automisation of the artwork and labelling generation. The practice of centralising the content in a web-based asset library and reusing those assets across all marketing and trade communications is saving businesses thousands, if not millions, of pounds.
More info >> |
|
|
